ANTIBODIES COMPOSITIONS AND METHODS FOR USE THEM
Patent Information
- Application Number
- DE602021028281
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-02-17
- Filing Date
- 2021-12-27
- Publication Date
- 2025-03-26
- Estimated Expiration
- 2041-12-27
AI Technical Summary
Current methods of delivering anti-PD-1 and/or anti-PD-L1 antibodies require periodic intravenous administration, which is inconvenient for patients and negatively impacts their experience, highlighting a need for alternative delivery methods such as subcutaneous administration using auto injectors or wearable pumps.
A pharmaceutical composition comprising an anti-PD-1 antibody, an endoglycosidase hydrolase enzyme, and antioxidants, specifically formulated for subcutaneous delivery, including nivolumab, histidine, sucrose, polysorbate 80, pentetic acid, and rHuPH20, to facilitate improved patient compliance and treatment convenience.
The subcutaneous delivery of the pharmaceutical composition enhances patient compliance and treatment convenience, allowing for potentially life-saving therapy to be administered in a comfortable home setting while maintaining therapeutic effectiveness.